Vystar Corporation Reports 59.7% Revenue Decline and $1.5M Net Loss for Fiscal Year 2025

Vystar Corporation reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with total revenues of $54,821, a decrease of 59.7% from $135,969 in 2024. The company attributed this drop primarily to reduced sales to a former major customer and the absence of a special bulk sale of Vytex products that occurred in the previous year. Gross profit also fell to $31,815, down 54.3% from $69,641 in 2024. The company's operating expenses decreased by 31.2% to $1,092,355, largely due to a temporary suspension of consulting fees and a reduction in professional fees as litigation matters wound down.

In terms of profitability, Vystar reported a net loss of $1,531,850 for 2025, compared to a net income of $2,520,312 in 2024, which included substantial income from discontinued operations related to the closure of Rotmans Furniture. The loss from discontinued operations was $456, marking a complete turnaround from the previous year's income of $4,192,379. The accumulated deficit at the end of 2025 stood at approximately $61.4 million, reflecting ongoing financial challenges.

Strategically, Vystar has focused on expanding its product offerings, particularly in the air purification and natural rubber latex markets. The company has been working on enhancing its RxAir product line, which utilizes patented air purification technology, and has entered into a market development agreement with Corrie MacColl to expand the distribution of its Vytex Natural Rubber Latex. Additionally, Vystar is exploring new product lines, including mattresses and bedding made from Vytex latex, to capture a larger share of the consumer market.

Operationally, Vystar's customer base has been affected by the loss of a major client, which previously accounted for a significant portion of its sales. The company is actively reviewing its pricing and sales strategies to regain market traction. As of December 31, 2025, Vystar had a cash position of $4,454 and a working capital deficit of approximately $6.6 million, raising concerns about its ability to continue as a going concern. The company plans to finance its operations through cash on hand, increased sales from RxAir products, and potential capital raises.

Looking ahead, Vystar's management has expressed cautious optimism about the future, emphasizing the need for increased revenue generation and successful product launches to stabilize its financial position. However, the company acknowledges the risks associated with market conditions and competition, particularly in the air purification and latex industries. The outlook remains uncertain, with management indicating that failure to achieve projected revenue levels could necessitate significant operational changes or even bankruptcy.